First human test of AZD4076 for fatty liver begins
NCT ID NCT02612662
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new drug called AZD4076 in 40 healthy men to see if it is safe and how the body processes it. The drug is being developed for non-alcoholic steatohepatitis (NASH), a serious liver condition. This is an early, first-in-human trial, so it focused only on safety and drug levels, not on treating the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-ALCOHOLIC STEATOHEPATITIS (NASH) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Brooklyn, Maryland, 21225, United States